Disease · MONDO_0005904

pericarditis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pericarditis. Diseases, record MONDO_0005904. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005904

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pericarditis; Open Targets
Open Targets ID: MONDO_0005904; Open Targets
Other names: inflammation of pericardium, pericarditis (disease), pericardium inflammation; Open Targets
Disease Ontology: DOID:1787; Disease Ontology
MeSH: D010493; MeSH
NCI Thesaurus: C34915; NCI Thesaurus
Orphanet: ORPHA:58208; Orphanet
Highest stage of its drugs: Approval, for 1 of its 7 drugs, from DailyMed; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RILONACEPT	CHEMBL1201830	Protein	Approval	DailyMed	4	2	2	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GOFLIKICEPT	CHEMBL4650513	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/1268	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Approval	https://conductscience.org/library/genes/3553	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3554	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03737110	Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis	Phase 3	86	2021-07-13	Recurrent Pericarditis	RILONACEPT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT05494788	Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)	Phase 2	27	2025-10-20	Recurrent Pericarditis	CANNABIDIOL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03980522	A Pilot Study of KPL-914 in Recurrent Pericarditis	Phase 2	26	2021-05-27	Recurrent Pericarditis	RILONACEPT	Its record names the disease	ClinicalTrials.gov
NCT03148236	Vitamin C in Atrial Fibrillation Ablation	Phase 2	20	2019-04-16	Atrial Fibrillation Ablation	ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03224585	Treatment of Acute Pericarditis With Anakinra	Phase 2	5	2021-02-23	Acute Pericarditis	ANAKINRA	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00810849	A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis	Phase 3	1,400		Tuberculous Pericarditis	PREDNISOLONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00128453	Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences	Phase 3	240		Pericarditis	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT06708299	CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)	Phase 3	110		Recurrent Pericarditis	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT05107934	Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis	Phase 2/3	80		Recurrent Pericarditis	GOFLIKICEPT	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vitamin C vs Placebo: deaths from any cause	0 of 10	0 of 10	20	NCT03148236	Trial comparisons
Vitamin C vs Placebo: serious adverse events	0 of 10	0 of 10	20	NCT03148236	Trial comparisons
Anakinra (3 Days) Then Anakinra (4 Days) vs Anakinra (3 Days) Then Placebo (4 Days): deaths from any cause	0 of 2	0 of 3	5	NCT03224585	Trial comparisons
Anakinra (3 Days) Then Anakinra (4 Days) vs Anakinra (3 Days) Then Placebo (4 Days): serious adverse events	0 of 2	3 of 3	5	NCT03224585	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33229362	RESULT	1	PubMed
42432451	DERIVED	1	PubMed
39044797	DERIVED	1	PubMed
39022168	DERIVED	1	PubMed
38471825	DERIVED	1	PubMed
37163222	DERIVED	1	PubMed
36316102	DERIVED	1	PubMed
36250662	DERIVED	1	PubMed
33882846	DERIVED	1	PubMed
32866928	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005904

GET https://conductscience.org/api/diseases/v1/MONDO_0005904/drugs

API reference For AI assistants